Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose?

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 4, 2006, Pages 1168-1173

  Pos, Floris J ^a   Hart, Guus ^a   Schneider, Christoph ^a   Sminia, Peter ^b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alpha beta ratio; Bladder cancer; Fractionation; Radiotherapy; Total dose

Indexed keywords

FRACTIONATION; LOGIC DESIGN; MATHEMATICAL MODELS; RADIOTHERAPY; TUMORS;

ALPHA/BETA RATIO; BLADDER CANCER; TOTAL DOSE;

PATIENT TREATMENT;

ARTICLE; BLADDER CANCER; BRACHYTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CONFIDENCE INTERVAL; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STATISTICAL MODEL; TREATMENT OUTCOME;

BRACHYTHERAPY; CONFIDENCE INTERVALS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LOGISTIC MODELS; RADIOBIOLOGY; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 33644510453     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.09.023     Document Type: Article

References (48)

1. L. Sengelov, H. von der Maase Radiotherapy in bladder cancer Radiother Oncol 52 1999 1 14
2. M.K. Gospodarowicz, W.D. Rider, C.W. Keen Bladder cancer Long-term follow-up results of patients treated with radical radiation Clin Oncol R Coll Radiol 3 1991 155 161
3. R.A. Cowan, C.A. McBain, W.D. Ryder Radiotherapy for muscle-invasive carcinoma of the bladder Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy Int J Radiat Oncol Biol Phys 59 2004 197 207
4. F.J. Pos, G. van Tienhoven, M.C. Hulshof Concomitant boost radiotherapy for muscle invasive bladder cancer Radiother Oncol 68 2003 75 80
5. L. Moonen, H. van der Voet, S. Horenblas Feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder Int J Radiat Oncol Biol Phys 37 1997 537 542
6. A.A. Yavuz, M.N. Yavuz, G.K. Ozgur Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer Int J Radiat Oncol Biol Phys 56 2003 734 745
7. A.N. Scholten, J.W. Leer, C.D. Collins Hypofractionated radiotherapy for invasive bladder cancer Radiother Oncol 43 1997 163 169
8. W. De Neve, M.L. Lybeert, C. Goor Radiotherapy for T2 and T3 carcinoma of the bladder The influence of overall treatment time Radiother Oncol 36 1995 183 188
9. W.U. Shipley, M.A. Rose, T.L. Perrone Full-dose irradiation for patients with invasive bladder carcinoma Clinical and histological factors prognostic of improved survival J Urol 134 1985 679 683
10. A. Pollack, G.K. Zagars, D.A. Swanson Muscle-invasive bladder cancer treated with external beam radiotherapy Prognostic factors Int J Radiat Oncol Biol Phys 30 1994 267 277
11. W. Majewski, B. Maciejewski, S. Majewski Clinical radiobiology of stage T2-T3 bladder cancer Int J Radiat Oncol Biol Phys 60 2004 60 70
12. F.J. Pos, S. Horenblas, J. Lebesque Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer Int J Radiat Oncol Biol Phys 59 2004 696 705
13. Pos F, Hulshof M, Lebesque J, et al. Adaptive radiotherapy for invasive bladder cancer: A feasibility study. Int J Radiat Oncol Biol Phys. In press.
14. D. Yan, D. Lockman, D. Brabbins An off-line strategy for constructing a patient-specific planning target volume in adaptive treatment process for prostate cancer Int J Radiat Oncol Biol Phys 48 2000 289 302
15. B. Maciejewski, S. Majewski Dose fractionation and tumour repopulation in radiotherapy for bladder cancer Radiother Oncol 21 1991 163 170
16. A. Horwich, D. Dearnaley, R. Huddart A randomised trial of accelerated radiotherapy for localised invasive bladder cancer Radiother Oncol 75 2005 34 43
17. G.G. Steel, J.M. Deacon, G.M. Duchesne The dose-rate effect in human tumour cells Radiother Oncol 9 1987 299 310
18. D. Banasiak, A.R. Barnetson, R.A. Odell Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line Radiat Oncol Investig 7 1999 77 85
19. E.M. Van der Steen-Banasik, A.G. Visser, J.G. Reinders Saving bladders with brachytherapy Implantation technique and results Int J Radiat Oncol Biol Phys 53 2002 622 629
20. F. Pos, S. Horenblas, P. Dom Organ preservation in invasive bladder cancer Brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys 61 2005 678 686
21. A. Wijnmaalen, P.A. Helle, P.C. Koper Muscle invasive bladder cancer treated by transurethral resection, followed by external beam radiation and interstitial iridium-192 Int J Radiat Oncol Biol Phys 39 1997 1043 1052
22. M. Pernot, J. Hubert, F. Guillemin Combined surgery and brachytherapy in the treatment of some cancers of the bladder (partial cystectomy and interstitial iridium-192) Radiother Oncol 38 1996 115 120
23. P. Nilsson, H.D. Thames, M.C. Joiner A generalized formulation of the 'incomplete-repair' model for cell survival and tissue response to fractionated low dose-rate irradiation Int J Radiat Biol 57 1990 127 142
24. R.G. Dale The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy Br J Radiol 58 1985 515 528
25. H.D. Thames An 'incomplete repair' model for survival after fractionated and continuous irradiation Int J Radiat Biol 47 1985 319 339
26. P. McCullagh, J.A. Nelder Generalized linear models 2nd ed 1989 Chapman and Hall London
27. E.K. Rofstad Radiation biology of malignant melanoma Acta Radiol Oncol 25 1986 1 10
28. K.R. Trott The optimal radiation dose per fraction for the treatment of malignant melanomas Int J Radiat Oncol Biol Phys 20 1991 905 907
29. S.M. Bentzen, M. Baumann The linear-quadratic model in clinical practice G.G. Steel Basic clinical radiobiology 3rd ed 2002 Arnold London 134 146
30. S.M. Bentzen, J. Overgaard, H.D. Thames Clinical radiobiology of malignant melanoma Radiother Oncol 16 1989 169 182
31. H.D. Thames, H.D. Suit Tumor radioresponsiveness versus fractionation sensitivity Int J Radiat Oncol Biol Phys 12 1986 687 691
32. J.F. Fowler, R.J. Chappell, M.A. Ritter Is the α/β ratio for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
33. D.J. Brenner, A.A. Martinez, G.K. Edmundson Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
34. H.D. Thames, S.M. Bentzen, I. Turesson Time-dose factors in radiotherapy A review of the human data Radiother Oncol 19 1990 219 235
35. J.F. Fowler, M.J. Lindstrom Loss of local control with prolongation in radiotherapy Int J Radiat Oncol Biol Phys 23 1992 457 467
36. G.D. Wilson, N.J. McNally, S. Dische Cell proliferation in human tumours measured by in-vivo labeling with bromodeoxyuridine Br J Radiol 61 1988 419 422
37. A.C. Begg, K. Haustermans, A.A. Hart The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer A multicenter analysis Radiother Oncol 50 1999 13 23
38. A. Pollack, G.K. Zagars, G. Starkschall Prostate cancer radiation dose response Results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
39. J.S. Belderbos, K. De Jaeger, W.D. Heemsbergen First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy Radiother Oncol 66 2003 119 126
40. M. Kleineidam, H.H. Dubben Overall treatment time in the radiotherapy of transitional cell cancer of the bladder Radiother Oncol 23 1992 270 271
41. D.J. Brenner Fractionation and late rectal toxicity Int J Radiat Oncol Biol Phys 60 2004 1013 1015
42. S. Dische, M.I. Saunders, R. Sealy Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy A report of a randomised controlled trial Radiother Oncol 53 1999 93 98
43. M. Gospodarowicz Radiotherapy and organ preservation in bladder cancer Are we ignoring the evidence? J Clin Oncol 20 2002 3048 3050
44. W.U. Shipley, A.L. Zietman, D.S. Kaufman Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates-the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences Semin Radiat Oncol 15 2005 36 41
45. C. Rödel, C. Weiss, R. Sauer Organ preservation by combined modality treatment in bladder cancer The European perspective Semin Radiat Oncol 15 2005 28 35
46. A. Chakravarti, K. Winter, C.L. Wu Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy A report from the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 62 2005 309 317
47. J.L. Dominguez-Escrig, J.D. Kelly, D.E. Neal Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer Clin Cancer Res 10 2004 4874 4884
48. J.E. Nutt, H.P. Lazarowicz, J.K. Mellon Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2 Br J Cancer 90 2004 1679 1685